CARMEL, Ind., Jan. 21, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing ...

NeurAxis, a neuromodulation tech company, offers IB-Stim, the only FDA-cleared device for treating IBS-related pain in children, promising revenue growth and profitability. The IB-Stim device ...

NeurAxis’ PENFS technology, IB-Stim, is FDA-cleared for functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents 8-21 years old. IB-Stim is a non-surgical device ...

NeurAxis, Inc. has announced its achievements from 2024 and outlined its vision for 2025 in a letter from CEO Brian Carrico. The company, focusing on neuromodulation therapies for chronic ...

NeurAxis (NRXS) announced that CEO Brian Carrico has published a letter to shareholders. “We are thrilled to connect with you as we celebrate NeurAxis’s remarkable achievements in 2024 and ...

NeurAxis (NYSE:NRXS) filed preliminary prospectus to offer and sell up to $25M mixed shelf offerings. The company also filed for offering of 6.5M shares of common stock by the Selling Stockholders.

CARMEL, Ind., Jan. 21, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing ...

NeurAxis is dedicated to advancing science and leveraging evidence-based medicine to drive the adoption of its IB-Stim™ therapy, which is its proprietary Percutaneous Electrical Nerve Field ...

NeurAxis’ PENFS technology, IB-Stim, is FDA-cleared for functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents 8-21 years old.

CARMEL, Ind., Jan. 21, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company ...

NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children ...